PMID: 7580546Oct 7, 1995Paper

Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group

BMJ : British Medical Journal

Abstract

To evaluate the effect of cytotoxic chemotherapy on survival in patients with non-small cell lung cancer. Meta-analysis using updated data on individual patients from all available randomised trials, both published and unpublished. 9387 patients (7151 deaths) from 52 randomised clinical trials. Survival. The results for modern regimens containing cisplatin favoured chemotherapy in all comparisons and reached conventional levels of significance when used with radical radiotherapy and with supportive care. Trials comparing surgery with surgery plus chemotherapy gave a hazard ratio of 0.87 (13% reduction in the risk of death, equivalent to an absolute benefit of 5% at five years). Trials comparing radical radiotherapy with radical radiotherapy plus chemotherapy gave a hazard ratio of 0.87 (13% reduction in the risk of death; absolute benefit of 4% at two years), and trials comparing supportive care with supportive care plus chemotherapy 0.73 (27% reduction in the risk of death; 10% improvement in survival at one year). The essential drugs needed to achieve these effects were not identified. No difference in the size of effect was seen in any subgroup of patients. In all but the radical radiotherapy setting, older trials using long...Continue Reading

References

Jan 1, 1978·Cancer Chemotherapy and Pharmacology·K KarrerH Denck
Dec 10, 1977·British Medical Journal·H StottD A Galton
Feb 1, 1992·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·J E TillE M Meslin
Dec 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A NiiranenS Pyrhönen
Aug 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R CellerinoG Fatati
Apr 1, 1985·International Journal of Radiation Oncology, Biology, Physics·J R SimpsonD V Rao
Mar 1, 1988·European Journal of Cancer & Clinical Oncology·K MattsonE Nordman
Mar 1, 1985·Progress in Cardiovascular Diseases·S YusufP Sleight
Mar 1, 1987·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·P MinetG Lennes
Apr 1, 1987·Statistics in Medicine·R Peto
Sep 1, 1986·Controlled Clinical Trials·R DerSimonian, N Laird
Aug 1, 1971·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·K W BrunnerW Müller
Jun 16, 1993·Journal of the National Cancer Institute·A GregorH H Hansen
Dec 1, 1993·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L CrinòM Tonato

❮ Previous
Next ❯

Citations

Feb 5, 2000·Seminars in Surgical Oncology·R Rosell, E Felip
Feb 22, 2002·International Journal of Cancer. Journal International Du Cancer·Christos KosmasHaralambos P Kalofonos
Mar 22, 2003·Irish Journal of Medical Science·R M RutherfordJ J Gilmartin
Dec 21, 2004·Der Internist·P Drings
Jul 24, 2010·Der Radiologe·A PrasseJ Müller-Quernheim
May 15, 2012·Cancer Immunology, Immunotherapy : CII·Runmei LiHui Li
Jun 7, 2005·Cancer Chemotherapy and Pharmacology·Athanasios AthanasiadisGeorge P Stathopoulos
Mar 24, 2006·Cancer Chemotherapy and Pharmacology·J FeliuM Gonzalez-Barón
Mar 28, 2006·Cancer Chemotherapy and Pharmacology·Yoshinobu IwasakiTsunehiko Nishimura
Sep 30, 2006·Cancer Chemotherapy and Pharmacology·Masahiro TabataUNKNOWN Okayama Lung Cancer Study Group
Dec 5, 2006·Cancer Chemotherapy and Pharmacology·Masafumi KawamuraKoichi Kobayashi
Jun 6, 2007·Cancer Chemotherapy and Pharmacology·Lin Run WangXiu Hua Wu
Aug 25, 2007·Cancer Chemotherapy and Pharmacology·Nanae TomonagaUNKNOWN Nagasaki Thoracic Oncology Group
Jan 14, 2009·Cancer Chemotherapy and Pharmacology·Joaquín Casal RubioUNKNOWN Galician Group of Lung Cancer (GGCP in the Spanish acronym)
Mar 24, 2009·Cancer Chemotherapy and Pharmacology·Yasuhiko KanoYusuke Furukawa
Aug 15, 2009·Cancer Chemotherapy and Pharmacology·Matthew K WongJames C Ho
Aug 11, 2010·Cancer Chemotherapy and Pharmacology·Athanasios G PallisVassilis Georgoulias

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.